This application belongs to the field of pharmaceutical chemistry and relates to the crystallization of aniline pyrimidine compounds as EGFR inhibitors. Specifically, this application relates to N (2 ((2 dimethylamino) ethyl (methyl) amino) ethyl (methyl) amino) 4 methoxy 8209;8209;8209 methyl 8209;8209 2 methyl 8209 2 8209; oxygen derivatives 2, 3 dihydrogen 8201hydrogen 8201H [d] benzo [benzo [benzo [benzo] imidazo [d] imidazo [d] imidazo [1] imidazolamlamlamThe Formation of Acrylamide (Form I) Hydrochloride with Pyrimidine-2-amino-phenyl Crystal A, B and C also relate to the preparation methods of crystalline A, B and C, the crystalline compositions comprising the crystalline A, B or C, the pharmaceutical compositions comprising the crystalline A, B and C or their crystalline compositions, and their pharmaceutical uses. The application for crystallization A, B and C has the advantages of high purity, high crystallinity and good stability.
【技术实现步骤摘要】
【国外来华专利技术】PCT国内申请,说明书已公开。
【技术保护点】
PCT国内申请,权利要求书已公开。
【技术特征摘要】
【国外来华专利技术】2016.06....
【专利技术属性】
技术研发人员:朱益忠,汤剑秋,刘飞,张喜全,顾红梅,朱波,王路路,汤松,张艳阳,
申请(专利权)人:正大天晴药业集团股份有限公司,连云港润众制药有限公司,北京赛林泰医药技术有限公司,
类型:发明
国别省市:江苏,32
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。